First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial

  • Hye Ryun Kim
  • , Shunichi Sugawara
  • , Jong Seok Lee
  • , Jin Hyoung Kang
  • , Naoki Inui
  • , Toyoaki Hida
  • , Ki Hyeong Lee
  • , Tatsuya Yoshida
  • , Hiroshi Tanaka
  • , Cheng Ta Yang
  • , Makoto Nishio
  • , Yuichiro Ohe
  • , Tomohide Tamura
  • , Nobuyuki Yamamoto
  • , Chong Jen Yu
  • , Hiroaki Akamatsu
  • , Shigeru Takahashi
  • , Kazuhiko Nakagawa

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science